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ABSTRACT 
Intestinal helminth infections remain a major health concern in developing areas of the world. 
Consequences of infection range from gastrointestinal discomfort to systemic manifestations. 
It has been suggested that individuals infected with intestinal helminths are more susceptible 
to other infections and mount weaker immunity to vaccination. Regions heavily burdened by 
intestinal helminths geographically coincide with areas plagued by infections with 
mycobacteria and the protozoan parasite Leishmania spp, causing tuberculosis (TB) and 
leishmaniasis, respectively. Further, it has been reported that people carrying intestinal 
worms mount weaker immune responses to the intradermally administered tuberculosis 
vaccine Mycobacterium bovis Bacillus Calmette Guérin (BCG). Intestinal helminth infections 
induce type 2 responses that aid in the expulsion of the worms, but also regulatory responses 
that facilitate chronicity of the worm infection. Both type 2 and regulatory responses are 
known to counteract type 1 immune responses required for protection against the intracellular 
pathogens mycobacteria and Leishmania, suggesting that worm infection may dampen 
protection to these infections. Yet, little is known about the systemic implications of intestinal 
worm infection, and the aim of the work in this thesis was to investigate the effects of 
intestinal helminth infection on skin immunity and control of co-infection. 
To this end, mice were infected with the strictly intestinal nematode Heligmosomoides 
polygyrus, and at various time points after infection subjected to secondary infection, 
immunization, or were culled. At the end of each experiment, composition and function of 
immune cells in skin, skin-draining lymph nodes (LNs), liver, spleen and other tissues 
involved in responses to secondary infection, were analysed. 
In Paper I, we found that mice infected with H. polygyrus were more susceptible to systemic 
infection with BCG and skin infection with Leishmania major. Increased susceptibility to 
BCG was accompanied by weaker IFN-γ production and fewer mycobacteria-specific 
transgenic p25 cells in spleen, and less inos expression and granuloma formation in livers. 
Delayed type hypersensitivity responses (DTH) induced in ears to BCG and L. major-derived 
antigens were dampened. Dendritic cell (DC) migration from footpad skin to the draining LN 
was reduced in worm-infected mice, as well as in mice where the footpad skin had been pre-
conditioned with either H. polygyrus excretory-secretory (HES) products or recombinant 
human transforming growth factor β (TGF-β). In vitro, BCG-induced IFN-γ production by 
mycobacteria-specific T cells was reduced by HES, soluble worm antigens, or by TGF-β. 
This led us to hypothesize that H. polygurus-induced reduction of immunity to the T helper 
cell type 1(TH1)-controlled organisms mycobacterium BCG and L. major was mediated by 
enhanced TGF-β production in worm-infected mice.  
In Paper II, we saw that (similar to the situation with H. polygyrus – BCG co-infected 
animals) worm-infected mice were more susceptible to systemic infection with the TH1-
controlled pathogen Leishmania donovani. Reduced protection was accompanied by lower 
inos levels and granuloma formation in livers and higher il10 levels in spleens.  
In Paper III, we sought for the explanation to the weaker skin immunity seen in worm-
infected mice (in Paper I). We found that mice infected with H. polygyrus had substantially 
smaller skin-draining LNs compared to worm-free animals. Both T cell and B cells were 
fewer, whereas no significant difference was observed in myeloid and stromal cell 
populations. As mentioned, numbers of DCs migrating from BCG-injected skin as well as 
p25 cells were less in skin-draining LNs of worm-infected mice. Notably however, numbers 
were directly proportional to the total number of cells in that particular LN. This led us to 
hypothesize that cells enter or are retained in an LN dependent on the original size of that 
node. As oppose to the atrophic skin draining LNs, the gut-draining mesenteric LNs were 
instead (as expected) dramatically increased in size. The lymphocyte pool cannot expand 
without limitation, and we suggested that worm-induced expansion of one LN occurred at the 
expense of other LN. Removal of worms restored the sizes of the non-draining nodes. 
However, this took time, since (according to out hypothesis) the atrophy of skin draining LNs 
and hyperplasia of mesenteric LN in itself decreased or increased infiltration or retention of 
cells into the respective nodes, maintaining this new “homeostasis”.  
In the last paper, Paper IV, we proceeded by investigating immune cells in the skin itself after 
H. polygyrus infection. We found that mice infected with H. polygyrus had fewer CD4+ cells 
producing IFN-γ in ear skin injected with whole cell lysate (WCL) from Mycobacterium 
tuberculosis in response to mycobacteria-specific ex-vivo re-stimulation, compared to worm-
free mice. IFN-γ production was also lower in the contralateral, untouched ear. Interestingly 
however, the total number of CD4+ cells were higher in ear skin of worm-infected mice. 
CD4+ T cell numbers were also higher when comparing H. polygyrus-infected and non-
infected animals without any skin stimulation, indicating that the intestinal infection, in itself, 
caused accumulation of CD4+ T cells in the skin. We found that the accumulated CD4+ T 
cells responded to H. polygyrus antigen by producing TH2 associated cytokines and that they 
remained in the skin for several weeks after removal of worms from the intestine. In 
accordance, skin-homing chemokine receptors were up-regulated on CD4+ T cells in the 
mesenteric LNs and blood. We hypothesized that the increased number of TH2 cells in the 
skin, in concert with the atrophy of skin draining LNs, were responsible for the lower 
protection to TH1-controlled organisms in the skin.  
In conclusion, mice chronically infected with the strictly intestinal nematode H. polygyrus 
were more susceptible to systemic and skin infection by TH1-controlled organisms compared 
to worm-free mice. We suggest that less inos and granuloma formation contributed to lower 
protection to systemic infection and that a combination of atrophic skin-draining LNs and 
increased numbers of TH2 cells in the skin caused weaker skin immunity. Taken together, this 
indicates that deworming may increase protection against secondary infection and increase 
beneficial effects of BCG vaccination.  
  
FOR ALL NON-INFECTION IMMUNOLOGISTS /  
FÖR ALLA ICKE-INFEKTIONSIMMUNOLOGER 
ENGLISH 
In the first draft of this text, I began by painting a picture of what my PhD defence party 
would have been like if I had graduated 100 years earlier. We would wear fringed dresses and 
cloche hats, do the Charleston, carry beaded flapper bags – and many of us would also carry a 
bundle of parasitic worms in our intestines. Several would have tuberculosis bacteria in their 
lungs, and the constant threat of malaria would still be upon us. Some that saw me register as 
a PhD student would not be there for the graduation, as they would have succumbed to the 
Spanish flu, a virus believed to have killed more people than the world war raging in Europe 
at the same time. The purpose of this introduction was to give people a glimpse of what a 
society strongly affected by infectious diseases was like; to describe a time when infections 
had a major impact on our daily lives and were a constant threat to our health and survival. 
And Stockholm in the roaring twenties was such a society. 
In the six months since that first draft was penned, another pandemic has showed us that also 
our modern society is highly vulnerable to infectious diseases, that they are not just a threat of 
the past. But unlike most written on infections right now, this thesis is not about Covid-19. 
Instead it is about those intestinal worms and other infections we would have had at that party 
in Stockholm 100 years ago. The infectious diseases we have basically eradicated in the West 
today – but which are still present in developing areas of the world, and thereby for most 
people living on this planet today. 
Many here in Sweden may have encountered small and harmless pinworms during 
kindergarten or primary school, but other than that, we are nowadays basically free from 
worm infections. In low-income countries the situation is very different. It is estimated that 
one fourth of the human population is infected with intestinal worms, highly concentrated to 
children in developing areas of the world. The most common species alone, “the large 
roundworm”, currently infects almost one billion humans. The large roundworm can reach 
0.6 cm in thickness and 30 cm in length and can (like many other worm species) cause 
intestinal symptoms, but also have outspread consequences for the infected person. For 
example, intestinal worms may cause problems with iron deficiency, stunted growth and 
reduced school performance. Most importantly for this thesis, they can also influence the 
immune system in a way that could change an individual’s ability to respond properly to 
vaccination or to protect themselves against other infections. 
Tuberculosis is rare in Sweden today, but still kills around 1.5 million persons every year in 
developing countries, and one third of the human population is latently infected with the 
bacteria causing tuberculosis. Just as scientists today struggle to find a vaccine against Covid-
19, at the time of my fictional defence party, Albert Calmette and his assistant Camille 
Guérin were at the Pasteur Institute in Paris finalizing their development of a vaccine against 
tuberculosis. They named their invention after themselves: Bacillus Calmette Guérin – or 
BCG, and 100 years later BCG remains the only vaccine we have against tuberculosis. BCG 
is the most used vaccine in the history of humankind and is still the first injection most 
newborn babies around the world experience. In Sweden we removed BCG from the national 
vaccine program in the 1970’s, but most Swedes born before then still carry the whitish scar 
on their upper arm as a memory of a time when tuberculosis was a major cause of death here 
as well. BCG is one of few vaccines still used today that actually contains live, although 
weakened, bacteria. However, it is debated whether or not BCG even protects against 
tuberculosis. When scientists are investigating the matter, some reports show that as many as 
80% of individuals receiving the vaccine are protected, whereas others show that it has no 
protective effect whatsoever. There are many hypotheses as to the reason behind these 
diverging results, and the outcomes of the studies partially seem to depend on where in the 
world the study is performed. As it happens, the areas where BCG does not seem to work are 
the same areas where intestinal worms are still common. In addition, researchers have seen 
that humans infected with intestinal worms actually do not get as good result from a BCG 
vaccination as a worm-free person. 
The reasons behind this observation are not fully known. A common hypothesis involves the 
fact that our immune system is divided into two major parts directed by two types of T cells, 
called TH1 and TH2. These two parts each consists of a bunch of cells and molecules 
specialized to combat a specific type of infection. TH1 fights bacteria and parasites that want 
to live inside of our cells. The tuberculosis bacteria, as well as the BCG vaccine bacteria, 
belong to this category. The TH2 section instead takes care of infectious organisms too big to 
fit inside a cell, such as intestinal worms. Interestingly, TH1 and TH2 do not only fight 
different infections, they also fight each other, and a good balance in between them is 
required for the immune system to function properly. In addition, a third fraction called TREG 
dampens (regulates) both TH1 and TH2, and TREG is also induced during intestinal worm 
infection.  
The aim of my PhD work was to investigate if the immune reactions induced by intestinal 
worm infections (TH2 and TREG) could change the whole immune system of the host so that 
they would be less protected against other infections or be more difficult to vaccinate. We 
have focused on infections where the body need TH1 reactions for protection or for initiating 
a vaccine response, and those infections that affect a separate part of the body than the gut 
where the worm is located. The BCG vaccination is delivered in the skin, and because of that 
we were also especially interested in investigating what happens in the skin after an intestinal 
worm infection. As mentioned, we were already aware that humans infected with worms 
could get weaker immune reactions to the BCG vaccine, but we wanted to understand the 
mechanism behind this observation. When investigating mechanisms behind a phenomenon 
that includes the whole body, animal experiments must be used, since many tissues are not 
possible to collect from humans for analysis. Although controversial, using animals for 
  
medical research is still our main tool to understand how our bodies work. Animal 
experiments have contributed enormously to the development of drugs and vaccines that have 
saved millions of human lives. Mice are the most commonly used animal since they are 
small, easy to handle, and reproduce fast, yet, because they are mammals, their molecules, 
cells and tissues are quite similar to ours.  
In our lab, we infect mice with an intestinal parasitic worm called Heligmosomoides 
polygyrus to imitate intestinal worm infection in humans. H. polygyrus is common in mice 
living in the wild, and the mice do not get noticeably sick from the infection. We infect the 
mice orally with the larval stage of the worm, and the larvae then migrate to the intestine of 
the mice where they develop into adult worms.  
In Paper I, we confirmed that mice – like humans – had weaker immune responses to the 
tuberculosis vaccine BCG when they were infected with worms. We also saw that worm-
infected mice were less protected against another infection by a small parasite that infects the 
skin, called Leishmania major. Infection with L. major causes lesions in the skin that may last 
for several months, and sometimes even years. Leishmania parasites are common in low-
income areas of the world where they are spread by a tiny fly called the sandfly. Like the 
tuberculosis bacteria, Leishmania parasites live inside of cells, hence, the body uses TH1 
immunity to fight Leishmania infections.  
There are several different types of Leishmania parasites, they all live inside of cells, but in 
different parts of the body. Paper II is about how intestinal worms affect immune responses 
to another type of Leishmania, causing so called visceral leishmaniasis and which attacks our 
inner organs. Visceral leishmaniasis (or Kala-azar, the “Black disease” in Hindi) is a deadly 
disease that kills 300,000 people every year in tropical regions, many of them in the north 
eastern parts of India where I travelled to a few times during my PhD. Visceral leishmaniasis 
is one of the most lethal infections existing in the world with almost 100% death rate without 
treatment, beating Ebola, HIV and malaria. Still the disease is unknown to most people living 
in the Western world, and is (along with intestinal worms) categorized by the WHO as a 
“Neglected tropical disease”, as it receives much less research funding and attention 
considering the death and suffering Leishmania causes. Visceral leishmaniasis can be caused 
by the Leishmania species Leishmania donovani. In Paper II we saw that mice that we had 
infected with intestinal worms were less protected against L. donovani with more Leishmania 
parasites in their liver and spleens compared to the mice without worms. As we expected, 
mice infected with worms had weaker TH1 responses in the infected organs.  
In Paper III, we aimed to understand the mechanism behind why mice infected with worms 
had weaker immune reactions to BCG. Surprisingly, we found a completely novel 
mechanism behind this, not including the TH1 and TH2 responses described earlier. When a 
person or mouse gets the BCG vaccine injected into their skin, the lymph nodes close to the 
skin are vital in initiating an immune reaction to the bacteria, a reaction that will prepare the 
body for a future tuberculosis infection. Surprisingly, we found that, in mice infected with 
intestinal worms these lymph nodes were smaller with fewer T cells, compared to lymph 
nodes of worm-free mice. Hence, we found a new mechanism that could explain why people 
infected with worms are more prone to having tuberculosis.  
We then wanted to see what was going on in the skin itself in mice infected with worms. In 
Paper IV, we found that mice infected with H. polygyrus had more memory TH2 cells in the 
skin, and these TH2 cells had likely travelled from the intestine to the skin. It is commonly 
believed that memory immune cells mostly appear at the body site where the infection is 
located, so that the next time the person gets infected with the same microbe, the memory 
cells are in the right position, ready to protect. Hence, the reason why our results were 
remarkable is that the memory cells appeared in a completely different location than where 
the worm was situated. In addition to the smaller lymph nodes seen in paper III, we believe 
that these TH2 cells in the skin may also contribute to the weaker vaccine responses to BCG 
seen in worm-infected mice.  
The risk of us Swedes again having to deal with intestinal worms and tuberculosis is minute, 
and since we do not have any sandflies, we probably do not have to worry about 
leishmaniasis either. Yet, the coronavirus has reminded us that infectious diseases are not just 
something to only think about when travelling to tropical and developing regions of the 
world. During this spring everyone has suddenly learned about T cells and what a long time it 
takes for the body to make antibodies. What maybe has been surprising to many is how little 
scientists know about immune responses to infections, as highly esteemed professors with 
seemingly the same education can have completely different views on how to deal with the 
situation. This is to a large extent because the immune responses to infections are extremely 
complex and multifaceted, and even though an immense amount of ground-breaking research 
is constantly being conducted all over the world, are we still far away from fully 
understanding and being able to predict how our immune system will react to a new infection. 
Hopefully, the work included in this thesis will bring us one (albeit small) step closer to that 
goal. 
SVENSKA 
I mitt första utkast till den här texten, inledde jag med att måla upp en bild av hur min 
disputationsfest skulle ha varit om jag tog examen för 100 år sedan. Vi skulle ha på oss 
fransiga klänningar och klockhattar, dansa Charleston och bära pärlprydda handväskor – och 
många av oss skulle även bära ett nystan av parasitiska maskar i våra tarmar. Flera skulle ha 
tuberkulosbakterier i sina lungor och hotet från malaria skulle vara konstant närvarande. 
Vissa som såg mig registreras som doktorand skulle inte ens vara där vid min examen, då de 
hade avlidit i spanska sjukan, ett virus som tros ha dödat fler personer än världskriget som 
samtidigt härjade i Europa. Tanken med introduktionen var att ge en bild av hur ett samhälle 
starkt påverkat av infektionssjukdomar tedde sig; att beskriva en tid då infektioner hade stort 
  
inflytande på våra dagliga liv och var ett konstant hot mot vår hälsa och överlevnad. Och 
Stockholm på det glada 20-talet var ett sådant samhälle.  
Ett halvår efter att det första utkastet skrevs, har nu ännu en pandemi visat oss att även det 
moderna samhället är sårbart inför infektionssjukdomar, att de inte bara är ett hot från det 
förflutna. Men till skillnad från det mesta som skrivs om infektioner just nu så handlar den 
här avhandlingen inte om covid-19. I stället handlar den om de inälvsmaskar och andra 
infektioner som vi skulle ha haft på festen i Stockholm för 100 år sedan. De där 
infektionssjukdomarna vi i västvärlden sedan länge blivit av med – men som fortfarande är 
närvarande i mindre utvecklade delar av världen, och därmed också för de flesta människor 
som lever på den här planeten i dag.  
Många här i Sverige kan ha stött på små och ofarliga springmaskar under dagis eller 
grundskolan, men utöver det så är vi i dag i princip helt fria från maskinfektioner i Sverige. I 
låginkomstländer är situationen mycket annorlunda. Det uppskattas att en fjärdedel av den 
mänskliga befolkningen är smittad med inälvsmask, och infektionerna är till mycket stor del 
koncentrerade till barn i utvecklingsländer. Den vanligaste arten, spolmask, står ensam för 
nästan en miljard infektioner. Spolmasken kan nå 0,6 cm i tjocklek och 30 cm i längd och kan 
(liksom många andra maskarter) orsaka tarmsymptom, men också ha mer utbredda 
konsekvenser för den smittade personen. Till exempel kan inälvsmaskar orsaka problem med 
järnbrist, dålig tillväxt och sämre prestation i skolan. Dessutom, och viktigast för denna 
avhandling: kan de påverka en persons immunsystem på ett sätt som kan förändra individens 
förmåga att reagera som man ska på vaccination eller förmågan att skydda sig mot andra 
infektioner. 
Tuberkulos är sällsynt i Sverige idag, men dödar fortfarande cirka 1,5 miljoner personer varje 
år i utvecklingsländer och en tredjedel av den mänskliga befolkningen är latent smittad med 
de bakterier som orsakar tuberkulos. Precis som forskare idag kämpar för att hitta ett vaccin 
mot covid-19 men vid tiden för min fiktiva disputationsfest, jobbade Albert Calmette och 
hans assistent Camille Guérin vid Pasteur-institutet i Paris för att färdigställa utvecklingen av 
ett vaccin mot tuberkulos. De uppkallade sin skapelse efter sig själva: Bacillus Calmette 
Guérin – eller BCG, och nu, 100 år senare, är BCG fortfarande det enda vaccinet vi har mot 
tuberkulos. BCG är det mest använda vaccinet i människans historia och är fortfarande den 
första injektionen som de flesta nyfödda barn världen över upplever. I Sverige tog vi bort 
BCG från det nationella vaccinationsprogrammet på 1970-talet, men de flesta svenskar födda 
före det bär fortfarande det vitaktiga ärret på överarmen som ett minne av en tid då tuberkulos 
var en vanlig dödsorsak även här. BCG är ett av få vacciner som används idag som faktiskt 
innehåller levande, dock försvagade, bakterier. Förvånande nog efter all tid som gått, 
diskuteras det fortfarande ifall BCG överhuvudtaget skyddar mot tuberkulos. När forskare 
undersöker saken visar vissa rapporter att så många som 80% av individerna som får vaccinet 
är skyddade, medan andra visar att det inte har någon skyddande effekt alls. Det finns många 
hypoteser till orsaken bakom dessa motsägande resultat, och utfallen av studierna verkar 
delvis bero på var i världen studien utförs. Som av en slump är många av de områden där 
BCG inte verkar fungera samma som de områden där inälvsmaskar fortfarande är vanliga. 
Dessutom har forskare sett att människor som är smittade med inälvsmask faktiskt inte verkar 
få lika bra resultat av en BCG-vaccination som en maskfri person. 
Anledningarna bakom dessa observationer är inte helt klargjorda. En vanlig hypotes bygger 
på att vårt immunsystem är uppdelat i två huvuddelar, organiserade av varsin typ av T-cell: 
TH1 och TH2. Dessa två delar består vardera av ett gäng celler och molekyler som är 
specialiserade på att bekämpa en specifik typ av infektion. TH1 bekämpar bakterier och 
parasiter som vill leva inuti våra celler. Tuberkulosbakterierna såväl som BCG-
vaccinbakterierna tillhör denna kategori. TH2-delen hanterar istället infektiösa organismer 
som är för stora för att få plats inne i en cell, såsom inälvsmaskar. Intressant nog bekämpar 
TH1 och TH2 inte bara skilda infektioner, de bekämpar också varandra, och det krävs en bra 
balans mellan dem för att immunsystemet ska fungera som det ska. Dessutom dämpar 
(reglerar) en tredje fraktion som kallas TREG både TH1 och TH2, och TREG framkallas också av 
inälvsmaskinfektion.  
Syftet med mitt doktorsarbete var att undersöka ifall immunreaktionerna framkallade av 
inälvsmask (TH2 och TREG) kan förändra värdens hela immunsystem så att de skulle vara 
mindre skyddad mot andra infektioner eller vara svårare att vaccinera. Vi har fokuserat på 
infektioner där kroppen behöver TH1-reaktioner för skydd, och på de infektioner som 
påverkar en separat del av kroppen än tarmen (där masken finns). BCG-vaccination ges i 
huden, och därför var vi särskilt intresserade av att undersöka vad som händer i huden vid 
inälvsmaskinfektion. Som nämnts visste vi redan att människor infekterade med maskar 
kunde få svagare immunreaktioner vid BCG-vaccination, men vi ville förstå mekanismen 
bakom detta för att kunna göra något åt det. När man undersöker mekanismer bakom ett 
fenomen som involverar hela kroppen måste man använda djurförsök, eftersom många 
vävnader inte är möjliga att samla in från människor för att kunna analysera. Även om det av 
många anses kontroversiellt är användning av djur för medicinsk forskning fortfarande vårt 
huvudsakliga verktyg för att förstå hur våra kroppar fungerar. Djurförsök har bidragit enormt 
mycket till utvecklingen av läkemedel och vaccin som har räddat miljontals människoliv. 
Möss är det mest använda djuret då de är små, lätta att hantera, och reproducerar snabbt. Men 
eftersom de är däggdjur har de flesta molekyler, celler och vävnader ganska lika våra.  
I vårt labb infekterar vi möss med en inälvsparasitisk mask som heter Heligmosomoides 
polygyrus, för att imitera inälvsmaskinfektion hos människor. H. polygyrus är vanligt hos 
möss som lever i naturen, och mössen blir inte märkbart sjuka av infektionen. Vi infekterar 
mössen oralt med larvstadiet av masken, och larverna migrerar sedan till tarmen hos mössen 
där de utvecklas till vuxna maskar. 
I Artikel I bekräftade vi att möss - liksom människor - hade svagare immunsvar mot 
tuberkulosvaccinet BCG när de var infekterade med mask. Vi såg också att maskinfekterade 
möss var mindre skyddade mot en annan infektion med en liten parasit som infekterar huden, 
  
som heter Leishmania major. Infektion med L. major orsakar sår på huden som kan finnas 
kvar i flera månader, ibland till och med år. Leishmania-parasiter är vanliga i de fattigaste 
områden av världen där de sprids av en liten fluga som kallas sandfluga. Liksom 
tuberkulosbakterierna lever Leishmania-parasiter inuti cellerna, därför använder kroppen 
TH1-immunitet för att bekämpa Leishmania-infektioner.  
Det finns flera olika typer av Leishmania-parasiter: de lever alla inuti cellerna, men i olika 
delar av kroppen. Artikel II handlar om hur inälvsmaskar påverkar immunsvaret mot en 
annan typ av Leishmania som orsakar så kallad visceral leishmaniasis och som istället 
angriper våra inre organ. Visceral leishmaniasis (eller Kala-azar, den "svarta sjukdomen" på 
hindi) dödar 50 000 – 90 000 människor varje år i de fattigaste delarna av världen, många av 
dem i nordöstra delen av Indien vartill jag har rest några gånger under min doktorandtid. 
Visceral leishmaniasis är en av de mest dödliga infektionerna som finns i världen med nästan 
100% fatalitet utan behandling, vilket slår ebola, HIV och malaria. Ändå vet de flesta 
människor som lever i västvärlden inte ens om att den finns. Visceral leishmaniasis är 
(tillsammans med inälvsmask) kategoriserad av WHO som en "försummad tropisk sjukdom", 
eftersom den får väldigt lite forskningspengar och uppmärksamhet proportionellt till hur 
mycket död och lidande den orsakar. Visceral leishmaniasis kan orsakas av Leishmania-arten 
Leishmania donovani. I artikel IV såg vi att möss som vi hade infekterat med H. polygyrus 
inte var lika bra på att skydda sig mot Leishmania donovani och hade fler Leishmania-
parasiter i sin lever och mjälte jämfört med möss som inte hade mask. Och som vi anade hade 
möss som vi infekterat med mask svagare TH1-svar i de infekterade organen. 
I Artikel III försökte vi förstå mekanismen bakom varför möss infekterade med maskar hade 
svagare immunreaktioner mot BCG. Vi hittade en helt ny mekanism bakom detta, oberoende 
av de TH1- och TH2-celler som beskrivits tidigare. När en person eller mus får BCG-vaccinet 
injicerat i huden är lymfkörtlarna nära huden viktiga för att starta en immunreaktion mot 
bakterierna och därmed för att förbereda kroppen på en framtida tuberkulosinfektion. 
Överraskande nog såg vi att hos möss infekterade med inälvsmaskar var dessa lymfkörtlar 
betydligt mindre med färre T-celler jämfört med lymfkörtlar hos maskfria möss. Därmed 
hittade vi en ny mekanism som kan förklara varför människor smittade med maskar är mer 
benägna att få tuberkulos. 
Vi ville sedan se vad som händer i själva huden hos möss infekterade med inälvsmask. I 
Artikel IV fann vi att möss infekterade med H. polygyrus hade fler minnesceller av TH2-typ i 
huden, och att dessa TH2-celler troligen hade färdats från tarmen till huden. Det antas att 
minnes-T-celler oftast uppkommer på samma ställen i kroppen som där infektionen är 
belägen, så att nästa gång personen smittas av samma mikrob, finns minnescellerna redan på 
rätt plats. Orsaken till att våra resultat var anmärkningsvärda att alltså att minnes-T-cellerna 
dök upp på en helt annan plats än där masken fanns. Utöver de mindre lymfkörtlarna från 
artikel II tror vi att dessa TH2-celler i huden också kan bidra till det svagare vaccinsvaret mot 
BCG vi ser hos maskinfekterade möss. 
Risken för att vi svenskar återigen skulle behöva hantera inälvsmaskar eller tuberkulos är 
väldigt liten, och eftersom vi inte har några sandflugor behöver vi förmodligen inte heller 
oroa oss för leishmaniasis. Däremot har coronaviruset påmint oss om att infektionssjukdomar 
inte bara är något man behöver tänka på när man reser till tropiska och mindre utvecklade 
delar av världen. Under våren har alla i Sverige plötsligt lärt sig vad T-celler är och hur lång 
tid det tar för kroppen att göra antikroppar. Men det som kanske har varit mest förvånande för 
många är hur lite forskare faktiskt vet om immunförsvar mot infektioner, då högt uppsatta 
professorer med till synes samma kunskap har haft helt olika åsikter om hur vi bäst ska 
hantera situationen. Detta beror mycket på att vårt immunsystem är extremt komplext och 
mångfacetterat, och även om en enorm mängd banbrytande forskning görs hela tiden över 
hela världen, är vi fortfarande långt bort från att förstå allt och att kunna förutsäga hur vårt 
immunsystem kommer att reagera på en ny infektion. Förhoppningsvis har arbetet bakom 
denna avhandling tagit oss ett (om än litet) steg närmare det målet. 
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1 INTRODUCTION 
A vast number of humans and animals around the world are infected with one or several 
species of parasitic worms, also known as helminths. Intestinal helminth infection may cause 
both local gastrointestinal (GI) symptoms and have systemic consequences for the host. Some 
of the latter involves disturbances in the balance of T helper (TH) cell subsets – vital for a 
well-functioning immune system. TH cells orchestrate the immune response in the direction 
appropriate for the nature of the infection, and protective immunity to helminths is mediated 
by TH cell type 2 (TH2)-driven immune reactions. In addition, regulatory responses which 
protects against immunopathology, but also facilitate establishment of chronic infection, are 
induced. There is still a substantial lack of knowledge regarding the effects intestinal worms 
have on our immune system (1, 2). This thesis focuses on the distal consequences by 
intestinal helminth infection, and more specifically, effects of intestinal worms on skin 
immunity and control of co-infection. 
1.1 T HELPER CELLS 
When pathogens first infect a host, they need to be detected, engulfed and presented by 
antigen presenting cells (APCs), such as dendritic cells (DCs) and macrophages, to initiate an 
adaptive immune response. Next, the APCs give instructions of their findings to the 
conductors of an adaptive immune response – the TH cells. TH cells orchestrate other immune 
cells via cytokines capable of triggering activation, inhibition, proliferation, and 
differentiation of the receiving cell (3). Below, the generation and function of lymphocytes, 
with focus on TH cells, are outlined. 
1.1.1 The lymphatic system 
The lymphatic system consists of primary (also called central) lymphoid organs (PLOs), 
secondary (also called peripheral) lymphoid organs (SLOs), and the lymphatic vessels. PLOs 
include the bone marrow from where all lymphocytes originate, and the thymus, responsible 
for T cell maturation. In the SLOs, adaptive immune responses to new antigens are initiated. 
SLOs include lymph nodes (LNs) and spleen, but also tissue specific structures such as 
tonsils, adenoids and the Peyer’s patches (PPs). The lymphatic vessels transport lymph in 
between lymphoid organs, blood, and non-lymphoid organs (NLOs) such as lung, fat, liver, 
kidneys, intestine and skin (3).  
1.1.2 Generation of T helper cells 
The T in T cell is short for “thymus-dependent”, as progenitors of T cells (thymocytes) 
migrate from the bone marrow to the thymus for maturation. B cells (short for “bursa of 
fabricius” where B cells where first found to mature in birds) mature completely in the bone 
marrow in mammals. The thymus is situated above the heart and consists of two lobes, each 
with an outer cortex and a central medulla. Cortex and medulla are separated by the cortico-
medullary region where the thymocytes enter. The newly arrived thymocytes start their 
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development into mature T cells in the cortex as double negative cells, expressing neither 
cluster of differentiation (CD) 4 nor CD8 T cell receptor (TCR) co-receptor molecules. 
Maturation is initiated by the rearrangement of a TCR by variable, diversity, and joining (V, 
D and J) recombination, which together with random nucleotide insertions and deletions 
provide enormous variability to the T cell repertoire. During the TCR rearrangement, the cells 
will start to express both CD4 and CD8, thereby becoming double positive T cells. Double 
positive cells will first enter positive selection, where the cells that have succeeded in creating 
a functional TCR molecule capable of binding self-major histocompatibility complex-
(MHC)-peptide complexes are selected for survival. Depending on if the TCR binds to an 
MHC class II or an MHC class I molecule at this stage, the T cell will become either a CD4 
or CD8 single positive T cell, respectively. Single positive cells will migrate to the medulla 
where negative selection takes place. In the negative selection, cells with high affinity for 
self-MHC-peptide complexes are eliminated in order to remove possibly autoreactive cells. 
Specialized stromal cells in the thymus express tissue restricted antigens from peripheral 
organs to prevent autoimmune reactions to these tissues as well. Cells with intermediate 
affinity to self-MHC-peptide complexes may instead develop into regulatory T cells (TREGs, 
discussed in section 1.2.3). The process of negative selection results in so-called central 
tolerance. The great majority of T cells (around 95-97%) will fail either positive or negative 
selection and never leave the thymus, but instead be targeted for apoptosis. T cells that pass 
will leave the thymus as mature, single positive, naïve cells. Naïve T cells circulate between 
blood and SLOs in search for its cognate antigen presented by an APC (3-6).  
During aging, the thymus degenerates and the output of new cells decreases, a process known 
as thymic involution. In older humans, naïve T cells are mainly replenished by proliferation, 
whereas in mice the great majority still stems from thymic output. Yet, thymic involution 
occurs in both humans and mice (7). 
1.1.3 Initiation of a T helper cell response in the lymph node 
Adaptive immune responses are initiated in SLOs, of which TH cell activation in LNs is most 
central for this thesis. LNs are bean-shaped pale-yellow organs situated where afferent lymph 
vessels converge, whose function is to create a meeting hub for naïve T cells and activated 
DCs. LNs consist of a peripheral cortex and a central medulla, all encapsulated by the 
subcapsular sinuses (SCS). The cortex is divided into an outer cortex mainly comprising B 
cells and an inner area (paracortex) primarily consisting of T cells. The spleen has a similar 
organization, but filters antigens in blood instead of from NLO (3). 
Most immature DCs reside in NLOs, where they sample their environment in search for 
potentially harmful microbes. Pathogens are recognized by expression of pathogen associated 
molecular patterns (PAMPs) – i.e. molecules that are prevalent on the microbe and often 
essential for its fitness. Detection of PAMPs is done by various pattern recognition receptors 
(PRRs), abundant on DCs and other APCs. The most renowned PRRs are probably the toll-
like receptors (TLRs) and the nod-like receptors (NLRs), recognizing for example 
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Figure 1: Antigen capture and T cell priming. After an infection, DCs engulf pathogens and process them into
peptides (1), upregulate MHC-II-peptide complexes and co-stimulatory markers (2), and travel to the draining
LN through afferent vessels (3). Naïve T cells enter the LN through the HEVs (4). In the paracortical area of the
LN, DCs present antigens to T cells, which scans the DCs with their TCR. In the case of a match, the DC will
prime the T cell (5). The MHC-II-peptide complex will then bind the TCR (signal 1) and co-stimulatory markers
on the DC will bind to co-stimulatory receptors on the T cell (signal 2) which will induce cytokine production
from the T cell (signal 3). 
 
lipopolysaccharides (LPS; also called endotoxin) on gram-negative bacteria, lipoteichoic acid 
on gram-positive bacteria, and viral nucleic acids. Binding of a PAMP to the PPR can result 
in phagocytosis of the PAMP-expressing microbe as well as production of cytokines, 
chemokines and antimicrobial substances. DCs process the phagocytosed pathogens into 
peptide fragments for presentation on MHC molecules, and the APC thereby becomes 
activated. Activation causes the DC to downregulate tissue retention markers and instead 
upregulate markers that will allow it entry into the LN, such as CCR7. In addition, the DC 
will upregulate activation markers such as CD80 and CD86 (also called B7.1 and B7.2, 
respectively) required to stimulate naïve T cells. Active DCs travel in the lymph to a draining 
LN, which they enter through afferent vessels into the SCSs and continue to the paracortex. 
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Antigens can also enter the LN free floating in the lymph and be engulfed by local DCs, 
macrophages, or B cells (which may induce a B cell response). Naïve lymphocytes 
circulating in blood instead enter the LN via the high endothelial venules (HEVs). HEV entry 
also leads to the paracortex, where the naïve lymphocytes meet with the activated DCs. Here 
the DCs present peptides on MHC-II and MHC-I to incoming CD4+ and CD8+ T cells, 
respectively. The entering T cells scan the peptide-MHC complexes with their TCRs. When a 
match is found, the T cell will become primed to activation by the DC (3). 
Priming of naïve TH cells by DCs occurs in three steps. Binding of the TCR-CD4 complex on 
the naïve T cell with the peptide-MHC II complex on the APC provides the signal one. Next, 
the co-stimulatory molecules (the activation markers) CD80 and CD86 on the DC bind to co-
stimulatory receptors on the T cell, such as CD28, conveying signal two. If the DC is not 
properly activated and lacks co-stimulatory molecules, the T cell will become anergic (non-
responsive) or tolerogenic. In addition to the activating co-stimulatory receptors, T cells also 
express inhibitory receptors such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), 
that balances the signal. Further, the DC will produce cytokines of various kinds depending 
on which PRR it was activated via, and these cytokines are sometimes referred to as signal 
three. Depending on where in the body the pathogen was found and in which draining LN 
priming occurs, the T cell will upregulate specific chemokine receptors, promoting distinct 
tissue homing patterns. When primed, the T cell will proliferate dramatically by clonal 
expansion, differentiate into the appropriate TH effector cell subset (discussed below) and 
return to the infected site to exert its effector functions (3).  
1.1.4 T helper cell subsets 
The functions of TH cells are to enforce, balance and direct the immune response onto a path 
appropriate to control the invading pathogen and simultaneously limit tissue damage. To 
achieve this, TH cells differentiate into various subsets producing distinct cytokine repertoires 
aiding the host to combat separate sorts of pathogens (3).  
The first indication that the mammalian immune system is orchestrated by subsets of TH cells 
was published in the 1980’s, when Mitchell et al found that genetically different mice 
developed distinct immune responses to the intracellular protozoan parasite Leishmania 
major (8). C57BL/6 mice displayed a resistant phenotype with local skin manifestations 
whereas BALB/C mice were more susceptible and developed disseminated disease with 
rampant parasite propagation (8). That this could be attributed to different TH cell populations 
with separate functionality was later demonstrated by Mosmann et al who named them TH1 
and TH2 (9). TH1 cells were seen to produce interferon (IFN)-γ and TH2 cells to produce 
interleukin (IL)-4 (9). TH1 cells and IFN-γ promoted cellular immunity that was seen to be 
protective against intracellular bacteria and parasites such as L. major, whereas TH2 cells and 
IL-4 were detrimental for L. major control TH2 cells and IL-4 were instead shown to mediate 
protective immunity to helminths (discussed in chapter 1.2.2) (10, 11). TH1 and TH2 cells act 
antagonistically on each other, as IFN-γ dampens IL-4 production and vice versa. This 
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Figure 2: Differentiation into TH cell subsets. Plus (+) indicates effector responses of the cells and minus (-)
indicates common unwanted consequences. 
dichotomy stood ground until early 2000 when the universe of TH cell subtypes started to 
expand. The anti-inflammatory TREG cells were discovered first (discussed in chapter 1.2.3) 
followed by the pro-inflammatory TH17 cells producing IL-17. TH17 cells are protective 
against extracellular bacteria and fungi and has been seen to promote several autoimmune 
conditions including psoriasis and rheumatoid arthritis (RA) (12, 13). Both TH1 and TH2 cells 
dampen TH17 responses. IL-17A has however been seen to be important for the induction of 
TH2 responses during helminth infection but to later dampen it, demonstrating the complexity 
of TH cell regulation (14). Next TH cell type to be discovered were the follicular TH cells 
(TFH) which were shown to orchestrate B cell responses in germinal centres. Two cell types 
are still under debate whether they should be considered their own subsets or included under 
TH2 and TH17 respectively, namely TH9 and TH22 cells. TH9 cells promote mast cell 
recruitment and activation and are as TH2 cells involved in helminth defence, whereas TH22 
cells promotes epithelial integrity (14, 15).  
1.1.5 Immunological memory and vaccination 
An adaptive immune response does not only protect the individual during the infection but 
leaves a trace of better preparedness for infection by the same pathogen, referred to as 
immunological memory. As previously described, when T cells are primed in the LN, 
effector TH cells with appropriate functions expand to fight the ongoing infection. In addition, 
memory cells that will outlive the effector response develop. Memory TH cells are typically 
divided into three types dependent on what tissues they patrol: central memory cells (TCMs), 
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effector memory cells (TEMs), and the most recent discovery – tissue resident memory cells 
(TRMs). All memory (and effector) cells express the activation marker CD44 by which they 
can be distinguished from naïve cells. TCMs circulate through blood and SLOs, and express 
markers such as CD62L and CC chemokine receptor (CCR) 7, allowing them to (like naïve 
cells) enter SLOs through the HEVs. TEMs have lost expression of these markers, and instead 
circulate between blood and NLOs. TRMs are believed to mainly remain in the NLOs, and if 
(and in that case how often) TRMs recirculate is debated. It seems that CD8+ TRMs are more 
stationary in the tissue whereas CD4+ TRMs are more motile and prone to recirculate (16). 
TRMs express the retention marker CD69 and some of them also CD103, the latter however to 
a varying degree. Like naïve cells, memory TH cells continuously sample MHC II-peptide 
complexes throughout the body. When a memory cell encounters its antigen, co-stimulation 
(“signal two”) is not required for activation, and any of the APCs, anywhere in the body, can 
activate a memory cell. In addition, this time around the response will be faster and stronger 
than the first time (16, 17). 
Immunological memory provides the possibility for vaccination, where for example an 
attenuated version or a component of a pathogen is given in a controlled manner in order to 
initiate an adaptive immune response. If the individual later is infected, the body will have 
developed memory cells able to give a rapid response to the infection. It is currently 
estimated that vaccination prevents around two to three million deaths every year around the 
world (16-18). 
1.1.6 Dynamics of lymphocyte recirculation 
Lymph refers to the semi-transparent liquid in the lymphatic vessels and contains cellular 
debris, immune cells (mainly lymphocytes), fatty acids, and microbes, all to a varying degree 
depending on body site. Lymph emerge when interstitial fluid is drained from the NLOs into 
blind ended lymphatic capillaries. These merge into larger (afferent) vessels which in turn 
converge at the LN draining the tissue. Lymph leaves the LN by efferent vessels which merge 
into the thoracic duct and is then emptied into the blood. Plasma is filtered out from the blood 
into the NLOs by capillary filtration, and some remain in the tissue as interstitial fluid which 
can again be collected as lymph. Lymph circulates due to pressure emerging from muscles 
when the body moves and can only travel in one direction due to intraluminal valves situated 
throughout the vessels, hindering backflow (19).  
At a given moment, most lymphocytes reside in the SLOs, many in tissues, and only around 
two percent in the peripheral blood. In a human, the total lymphocyte pool consists of around 
1012 lymphocytes. During homeostatic conditions, the number remains relatively constant by 
a balance of thymic output, peripheral proliferation and cell death. The cytokine IL-7, 
produced by stromal cells in lymphoid organs, is vital for T cell survival and for maintaining 
lymphocyte homeostasis (20). A naïve TH cell has been estimated to live around six to ten 
years in humans, but only around six to ten weeks in mice (7). The number of cells per TCR 
clone is highly heterogenous but is estimated to range between one in 106 to one in 105, and 
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Figure 3: Helminth prevalence
in an Indian population.
Samples were collected in Bihar,
India (2017) by Cajsa Classon. 
the magnitude of the response has been seen to depend upon the initial number of clonal cells 
(4, 21-23). 
Naïve lymphocytes enter LNs via the HEVs. HEVs act as gatekeepers for cell entry from the 
blood into an LN, maintaining the number of cells in the LN relatively constant during 
homeostatic conditions (24). When an LN is activated, more cells are allowed to pass the 
HEVs into the node, and in addition, fewer cells leave, a phenomenon known as “LN 
shutdown” which increases the size of the node. Levels of sphingosine-1-phosphate receptor 
(S1PR1) expression regulates LN egress (19). The ligand for S1PR1, sphingosine 1-
phosphate (S1P), is found at high levels in blood and lymph, but low levels in lymphoid 
organs. Hence, upregulation of the receptor causes cells to follow the gradient and leave the 
LN (19). Naive TH cells are highly motile within an LN with a mean velocity of around 10–
12 μm/min whereas DCs travel slower (2–6 μm/min) (22, 25). Each DC meet around 500-
5000 T cells per hour, and each contact last only around a few minutes if the displayed 
antigen is not a match with the TCR (22). Studies on lymphocyte travel time through LNs of 
mice indicates that CD4+ T cells travels the fastest, followed by CD8+ T cells, and that B 
cells moves the slowest through the node (22, 25-27). In mice, a naïve TH cell has been 
estimated to spend an average of 12.2 and 9.6 hours traveling through a peripheral and a 
mesenteric LN, respectively (27). 
1.2 INTESTINAL HELMINTHS 
The word helminth stems from the ancient Greek word hélminthos, meaning “intestinal 
worm”. Historically, all vertebrate animals, including humans, have been infected with 
intestinal worms for, probably, as long as their species have excited. Today, the burden of 
disease in humans is almost exclusively limited to developing countries and regions, where 
poor sanitary conditions contribute to dissemination of infection. In the 1930th, researchers set 
up the first experimental animal models of helminthic disease. These early studies laid 
grounds for further research, including studies on how our immune system is affected by 
presence of intestinal worms (28-30). 
1.2.1 Intestinal helminths in humans  
Intestinal helminths are widespread in most vertebrates, 
including humans. The number of people infected is not known, 
but the World Health Organization (WHO) estimates it to be 
more than 1.5 billion individuals, corresponding to 24% of the 
human population. The great majority of cases are found in 
developing countries and the disease burden of helminthiasis is 
severely neglected. Children in rural areas of many low-income 
countries are often infected by multiple helminth species 
simultaneously throughout a large part of their childhood (31, 
32). Intestinal helminths inhabit the GI tract of their host in the 
 22 
Figure 4: Eggs from Ascaris sp (A),
hookworm (B), and T. trichura (C).
Samples collected in Bihar, India (2017)
by Cajsa Classon. Photo by Nuno Sousa. 
adult stage of the life cycle, where they produce immense numbers of eggs that are excreted 
with the host’s faeces. Parameters such as poor accessibility to sanitary facilities, high 
population densities, and warm climate, increase the abundance of intestinal worms within a 
population (31, 32).  
Intestinal helminths infecting humans range from a few millimetres to several meters in size. 
They can be divided into three major groups based on morphology and means of nutrient 
acquisition and reproduction: nematodes (roundworms), cestodes (tapeworms) and 
trematodes (flukes). Nematodes are cylindrical in shape and range from a few millimetres up 
to 30 centimetres in length. They have a proper GI tract and most species have distinct male 
and female individuals. Cestodes are the lengthiest, and (although rare) individual worms 
have been shown to measure up to 30 meters. They attach to the intestinal mucosa with a 
head structure, called scolex. The body consists of a chain of flattened hermaphroditic 
segments (proglottids) that contains eggs and are released with the host’s faeces. Cestodes 
have no proper GI tract but absorbs nutrients from their host’s intestinal lumen through the 
tegument. The third group, flukes, have a GI tract and a solid body instead of proglottids. 
Many are hermaphroditic, except for the blood-flukes that have separate male and female 
individuals. Flukes are often quite small, ranging from a few millimetres up to around eight 
centimetres, and have a leaf-like shape. Around 300 helminth species have been found to 
infect humans but a small number of nematode species are responsible for the great majority 
of infections, namely Ascaris lumbricoides, Trichuris trichura and the two hookworm species 
Necator americanus and Ancylostoma doudenale (31-34).  
Many intestinal helminth infections are asymptomatic, but symptoms may range from mild 
local effects including intestinal discomfort, constipation or diarrhoea, to systemic 
implications such as deficits in nutritional status, reduced weight, stunted growth, cognitional 
complications, reduced school performance, and most important for this thesis: reduced 
vaccine efficacy and immunity to secondary infections. In addition, hookworms can cause 
iron-deficiency anaemia by attaching to the intestinal mucosa and feed on host blood. 
Intestinal worms infect by various routes including contaminated food or water (e.g. Ascaris 
spp. and T. trichura) and penetration of skin (e.g. hookworms). The skin infection route may 
cause itchiness and redness (ground itch) at the site of penetration. Some species, such as 
Ascaris spp. and hookworms, have extraintestinal larval migration routes bypassing the lungs, 
and may thereby cause lung manifestations such as wheezing or shortness of breath (2).  
 
 
  23 
1.2.2 Protective immunity to intestinal helminths 
During an intestinal helminth infection, the host initiates type 2 responses, orchestrated by 
TH2 cells, to expel the worms. Type 2 reactions in the intestines result in increased peristaltic 
movements, accelerated turnover of gut epithelial cells, and hyperplasia of goblet cells 
causing elevated mucus production – effects that are collectively referred to as the “weep-
and-sweep” response. The weep-and-sweep response is mediated primarily by the signature 
TH2 cytokines IL-4, IL-5 and IL-13, and by inflammatory mediators, histamines, and 
prostaglandins released by for example mast cells. In addition, type 2 responses result in 
eosinophilia and increased class-shifting to the IgE and IgG1 isotypes of antibodies. Most IgE 
immediately attach to the high affinity IgE receptor FcεRI on mast cells and basophils, and 
very little is free in serum. Eosinophils contain granules which content can damage the cuticle 
of the helminth. Type 2 responses are also elicited to allergens and during asthmatic 
reactions, and can have severe consequences if initiated in the skin or airways (3, 33). 
How a type 2 response is initiated is still not fully elucidated, but a number of mechanisms 
have been suggested, that are likely to be overlapping. IL-4 is crucial for type 2 immunity, 
yet, DCs (known as the fundamental bridge between the innate and adaptive immune 
response) does not produce IL-4 (35). DCs can however induce TH2 cells via Notch ligand 
and OX40 signalling (35). Basophils on the other hand can function as APCs to promote TH2 
differentiation and are significant producers of IL-4 (36). Epithelial cells damaged by the 
parasites produce alarmins such as thymic stromal lymphopoietin (TSLP), IL-25 and IL-33, 
known to induce type 2 immunity. Recent studies have identified tuft cells, a rare type of 
epithelial cell found at mucosal barriers, as an early source of type 2 cytokines (especially IL-
25), in the context or intestinal helminth infection (37). Innate lymphoid cells (ILCs) also 
serve as an early source of type 2 cytokines and amplifies the response (37). The transcription 
factors GATA3, signal transducer and activator of transcription (STAT) 6, and STAT5 
promotes TH2 differentiation and stimulates production of IL-4, IL-5 and IL-13. IL-4 
strengthens the TH2 profile and promote B cells to produce IgE. IL-5 mainly recruits and 
activates eosinophils, whereas IL-13 induces smooth muscle cell contraction (causing 
peristaltic movements of the intestine), increases mucus production by goblet cells, and 
promotes enterocyte shedding (3, 33).  
1.2.3 Regulatory responses during intestinal helminth infection 
Despite induction of type 2 responses aiming to expel intestinal helminths, worms often 
manage to stay in the gut and the infection becomes chronic. Chronicity of helminth infection 
is facilitated by strong induction of regulatory responses. Regulatory signalling acts broadly 
anti-inflammatory and dampens all other immune reactions (including type 2 responses) in 
order to limit immunopathology. Consequently, regulatory responses may help the worms to 
remain in the intestine (2). TREGs are central for regulatory signalling. There are two main 
subtypes of TREGs: natural TREGs (nTREGs, also called thymus-derived TREGs) which arise in the 
thymus, and induced TREGs (iTREGs, also called peripheral TREGs). iTREGs develop in the 
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Figure 5: Immune response during intestinal helminth infection. During an intestinal worm infection,
type 2 signalling triggers goblet cell hyperplasia (which causes thickening of the mucus layer) and enterocyte
shedding. TH2 cells and TREGs expand and mast cell and eosinophils accumulate.  
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periphery if the cell encounters its cognate antigen during inadequate co-stimulation. TREGs 
exert their suppressive function by a variety of mechanisms, including cell-cell contact, 
metabolic interference, and cytokines. TREGs are both induced by and produce the regulatory 
cytokines transforming growth factor β (TGF-β) and IL-10 and are defined by expression of 
the transcription factor forkhead box P3 (Foxp3). TGF-β is excreted in an inactive form that 
is stored in the extracellular matrix until activated enzymatically. Genetic absence of any of 
the components of the TGF-β pathway is lethal during the first weeks of life due to rampant 
inflammatory disease. During intestinal helminth infection, robust TGF-β production is 
induced by the host, and in addition, many helminths produce TGF-β homologues that acts 
on host cells to reinforce the response (further discussed in chapter 1.2.6) (38, 39). IL-10 was 
first categorized as a TH2 cytokine and does indeed mediate key TH2 functions such as 
activation of mast cells. Nowadays however, IL-10 is mainly considered a regulatory 
cytokine critical for dampening inflammation and for wound healing. IL-10 is produced by 
Foxp3 expressing TREGs but also by a Foxp3 negative population called type 1 regulatory 
(Tr1) cells, known for their high IL-10 production. Tr1 cells mediate immunosuppression by 
many of the same mechanisms as Foxp3+ TREGs and are known to dampen protective 
immunity during helminth infection (6, 33, 39-41).  
1.2.4 Macrophage subtype differentiation during worm infection 
Another immunological feature promoted by helminth infection is the development of an 
anti-inflammatory type of macrophages, M2 macrophages (also called alternatively activated 
macrophages [AAMs]), as opposed to the classically activated pro-inflammatory M1 
phenotype. M2 macrophages are induced by the type 2 cytokines IL-4 and IL-13 and are 
important for protective anti-helminthic immunity as well as healing of wounds caused by 
migrating helminth larvae. M2 and M1 macrophages differ in their ways to process arginine. 
M2 macrophages express the enzyme arginase-1 that synthesizes urea and ornithine from 
arginine. M1 macrophages are instead induced by IFN-γ and express the enzyme inducible 
nitric oxide (NO) synthase (iNOS) that generates citrulline and NO out of arginine, the latter 
which is vital for type 1 immunity in mice. As arginase-1 and iNOS compete for the same 
substrate and are activated by counter-inhibiting cytokines, M1 and M2 (like TH1 and TH2) 
act antagonistically against each other (42-44).  
1.2.5  Heligmosomoides polygyrus 
The work included in this thesis is centred around responses induced by the commonly used 
model organism Heligmosomoides polygyrus bakeri, previously known as Nematospiroides 
dubius, and onwards referred to as H. polygyrus. H. polygyrus is a strictly intestinal nematode 
and a natural parasite of mice. Out of the human-infecting helminths, H. polygyrus is 
taxonomically closest to hookworm, and the eggs are almost morphologically identical to 
those of hookworms. However, H. polygyrus lacks migratory route and does not feed on host 
blood. H. polygyrus infects orally as L3 stage larvae and enters the submucosa within the first 
24 hours after infection. The larvae moult twice (via L4 and L5 stages) in the intestinal wall, 
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before exiting into the lumen as adult worms around eight to ten days after infection. As 
adults, H. polygyrus inhabit the small intestine, where they are curled up around the villi and 
feed on the host’s intestinal tissue. After mating, the worms produce eggs which are excreted 
with the host’s faeces. Around six to eight days after release, the eggs hatch, and via L1 and 
L2 larval stages develop into new infective L3 stage larvae (2, 33, 45, 46). 
As most intestinal helminths, H. polygyrus induces type 2 responses in tissues close to the 
gut, such as mesenteric LNs, PPs, and lamina propria (LP). ILC2s are vital for induction of 
TH2 cells and for protective immunity against H. polygyrus (47). The type 2 cytokines IL-4, 
IL-13 and IL-9 are crucial for protection, whereas the roles of IL-5 and the accompanying 
eosinophils are not as clear (11, 48). Mast cells are involved in worm expulsion (45, 49) and 
B cells, M2 macrophages and basophils are important for protection against re-infection (43, 
50). The type 2 response peaks around two weeks after infection after which regulatory 
responses take over and dominate during the chronic stage (2, 33, 45, 47). During the tissue 
stage of infection, granulomas consisting of neutrophils, macrophages, DCs, and eosinophils 
form around the larvae in the submucosa. After reinfection, TH2 cells and M2 macrophages 
accounts for a large fraction of cells in the granulomas. Similar to natural helminth infection, 
H. polygyrus establishes chronic infection in many laboratory mouse strains, including the 
IFN-γ prone C57Bl/6. In more IL-4 skewed strains such as BALB/c, the infection is typically 
cleared within a few weeks (2, 33, 45). 
Figure 6: Life cycle of H. polygyrus. Mice are infected by ingestion of L3 stage larvae (1) that migrate to the
small intestine where they enter the submucosa (2). Here they moult twice and exit into the lumen as adult
worms eight to ten days after infection (3). Adult worms produce eggs that are shed in the host’s faeces (4). Eggs
will hatch in the environment (or in a moist Petri dish in the lab) and develop into new L3 stage larvae (5). 
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1.2.6 Excretory-secretory products 
Helminths produce a plethora of molecules known as excretory-secretory (ES) products. 
These include both by-products of the worms’ metabolism and lifecycle, as well as actively 
secreted molecules that can promote helminth establishment, survival and/or have 
immunomodulatory effects. Many acts to enhance regulatory responses, interfere with type 2 
immunity, or dampen deleterious inflammation. This is done by for example modulating DC 
polarization, reducing cell T proliferation, preventing cell migration, and inhibiting mast cell 
activation. ES products can also for example act as proteases and degrade host tissue or 
inhibit blood coagulation to facilitate blood feeding. Many ES products have been seen to 
reduce both systemic and organ specific inflammatory conditions and one molecule often 
confers several effects. Commonly, the different larval stages and adult worms produce a 
distinct setup of ES products, tailored to their needs. ES products consist of various types of 
molecules, including proteins, glycoproteins and lipids. The majority are polypeptides 
ranging from around ten to several hundreds of kilodaltons, and many are glycosylated. 
Production of ES products is evolutionary conserved, as they can be found in all helminth 
phyla (51-53). 
The first discovered ES product, ES-62, is still one of the most extensively studied ones and 
was found in the rodent filarial nematode Acanthocheilonema viteae. ES-62 is an example of 
a molecule with an array of mechanisms: it protects against neutrophil and eosinophil 
infiltration in the lung, induces IL-10 and blocks IL-17 production by T cells, and inhibits 
degranulation of mast cells (52, 54). Several ES products act on the TGF-β pathway and 
some of these have arisen by convergent evolution, indicating their significance for the fitness 
of the worms (53). One striking example is the so called TGF-β mimic produced by H. 
polygyrus (HpTGM), which functions as a TGF-β receptor ligand with similar effects as (but 
no structural homology to) mammalian TGF-β (38, 52, 55). HpTGM can induce Foxp3-
expressing regulatory T cells de novo (38, 52, 55). Interestingly, HpTGM can also act on 
human T cells, even though H. polygyrus does not infect humans (53). Another ES product of 
H. polygyrus known as H. polygyrus alarmin release inhibitor (HpARI) blocks the IL-33 
pathway both by suppressing its release from the nuclei of damaged epithelial cells and by 
binding directly to IL-33 (53, 56).  
1.2.7 Systemic dissemination of type 2 and regulatory immunity 
Many helminths have extra-intestinal larval migration routes passing though several tissues 
such as skin, blood, liver, and lungs. It is thus not surprising that a response is elicited in all 
organs encountering the migrating larvae. However, type 2 and regulatory cells and 
associated effector molecules have been observed at sites distal to the intestine also after 
infection with non-migrating helminths. It is established that humans and mice with intestinal 
worms have elevated levels of type 2 cytokines and eosinophils in the blood (57). The degree 
of TH2 cell and TREGs dissemination to NLOs has however only started to become 
investigated. In BALB/c mice infected with H. polygyrus, IL-4 producing TH2 cells detected 
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by a fluorescent reporter did not only expand in the vicinity of the gut, but had disseminated 
systemically two weeks after infection (58, 59). Most TH2 cells were found in 
bronchoalveolar lavage fluid, the peritoneal cavity and in the liver, and were still apparent 
(although diminished) four weeks after deworming (58). Similarly, others have shown that 
functionally protective tissue resident TH2 cells can be found in the peritoneal cavity eight 
weeks after deworming from H. polygyrus (60). Increased levels of Foxp3+ TREGs have been 
reported in axillary LNs, mediastinal LNs and spleen four weeks after H. polygyrus infection 
(61). Recently, regulatory myeloid-derived suppressor cells were seen to have disseminated 
to peritoneal fluid, blood and bone marrow of H. polygyrus-infected mice (62). 
1.3 HELMINTH CO-INFECTIONS 
Humans plagued by intestinal worms are to a large extent the same populations which are 
highly exposed to other infections. Due to the wide-spread effects of intestinal helminth 
infection on the host immune system, intestinal worms can be presumed to have implications 
on immunity to secondary infections and on vaccine responses. Effects have been 
investigated in humans and mice, but the results are generally diverging and varies with 
helminth species, secondary pathogen, secondary infection site, timing of infections, human 
population studied, or mouse strain employed. Further, a number of mechanisms for the 
observed effects have been proposed, including dissemination of type 2 responses, regulatory 
responses, or ES products, and alterations in the microbiota or in metabolic pathways (32, 63, 
64). 
Due to the inhibitory effects of type 2 cytokines on TH1 cells, infections requiring type 1 
immunity for protection can be expected to be especially affected by presence of intestinal 
worms. Mycobacteria, e.g. Mycobacterium tuberculosis causing tuberculosis (TB), and the 
protozoan parasites of the Leishmania spp. (causing various forms of leishmaniasis) are such 
pathogens. M. tuberculosis and Leishmania spp. are completely unrelated organisms and their 
disease pathogenesis distinct, yet, both live intracellularly with macrophages as main 
residence which causes the host to employ in many respects similar immune reactions for 
protection. TH1 responses are induced by IL-12 from APCs which will in turn promote 
production of the signature cytokine IFN-γ by TH cells. In mice, IFN-γ induce NO production 
in the infected cell, which will contribute to killing of the pathogen (65). In humans on the 
other hand, reactive oxygen species and antimicrobial peptides are more important for 
protection. The necessity of CD4+ T cells in defence against mycobacteria and Leishmania 
spp. is underscored by overrepresentation of human immunodeficiency virus (HIV) positive 
individuals among patients progressing to active disease and that succumb to the infections, 
as HIV specifically eliminates CD4+ cells (66, 67).  
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1.3.1 Intestinal helminths and mycobacteria 
TB has plagued humans for thousands of years and remains a leading cause of death by 
infectious diseases worldwide. TB is a disease of the poor and mainly affects developing 
areas of the world. Around ten million individuals progressed to active clinical disease from 
latent infection and around 1.5 million patients died from the disease in 2018. It is estimated 
that almost one third of the worlds’ population is latently infected with M. tuberculosis. 
However, only a minor part of the infected individuals (five to ten percent) develop active 
disease during their lifetime – a phenomenon highly influenced by the immunological status 
of the patient (66).  
In 1882, Robert Koch identified M. tuberculosis as the disease-causing agent of TB, and M. 
tuberculosis is indeed responsible for the great majority of TB cases. Other mycobacteria, 
such as Mycobacterium bovis may also case TB, but mainly in immunocompromised 
individuals. The only available vaccine against TB, Bacillus Calmette-Guérin (BCG), is a live 
attenuated form of M. bovis named after the developers Albert Calmette and Camille Guérin. 
Calmette and Guérin passaged M. bovis for attenuation at the Pasteur Institute in Paris, 
France, in the early 20th century, and used BCG as a vaccine against TB for the first time in 
1921. Since then, BCG is the most ever used vaccine in the history of mankind, but the 
estimated efficiency is highly variable between studies, ranging from zero to 80%. Protection 
has been shown highest in children, especially for protecting infants against meningeal and 
miliary TB, and lowest against pulmonary TB in adults. Several reasons have been suggested 
for the variable efficiency of the vaccine, including differences between BCG strains, 
geographic location of the study, host genetics and immune status, method of immunization, 
presence of environmental mycobacteria, and as discussed below, presence of co-infections, 
such as intestinal helminths (66, 68-73).  
BCG is administered as an intradermal injection into the skin. Active, latent or cleared TB 
infection, successful vaccination, or exposure to environmental mycobacteria can be detected 
by a so-called tuberculin skin test (TST; also known as Mantoux test), sometimes used to 
diagnose TB. A TST is performed by injecting purified protein derivate (PPD, a mixture of 
mycobacterial proteins) into the skin, which induces a delayed type hypersensitivity (DTH) 
reaction in exposed individuals. The diameter of the induration is measured 48 or 72 hours 
later and gives an indication of the robustness of the individual’s mycobacteria-specific 
cellular immune response (74). Areas heavily affected by helminths geographically overlap 
with areas with high TB burden and low BCG efficiency (76). It has been estimated that 
around 20-35% of TB patients are co-infected with, or have been exposed to, intestinal 
helminths (77). Proper control of mycobacterial infection is linked to TH1 cytokines and 
reactivation of TB disease has been associated with a shift towards TH2 cytokines in mice 
(78). Accordingly, patients with active TB have been reported to have a mixed TH1/TH2 
profile (79). Despite the theoretical support of that the TH2 response to intestinal worms 
would disturb development of proper TH1 immunity to TB, data from co-infection studies 
have been diverging. In some studies, higher prevalence of intestinal nematode infection has  
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Figure 7: Areas with high prevalence of
intestinal worms are geographically
overlapping with areas highly affected by TB
and leishmaniasis. Proportions of children (1-
14) years old in the country requiring treatment
for intestinal helminthiasis (WHO, 2014, A).
Estimated incidence rate of TB, (WHO, 2018,
B), CL (WHO, 2018, C) and VL (WHO, 2018,
D), around the world. 
been found in TB patients compared to 
healthy controls (58, 80-82), whereas 
other have shown no such association 
(83, 84). Intestinal nematode infection 
had no impact on progression from 
latent to active TB in HIV-infected TB 
patients in Uganda (85) and neither in a 
large longitudinal cohort study in India 
(86). However, HIV infected individuals 
are a complicated study population for 
the purpose due to low levels of the 
critical CD4+ T cells (85). In the 
Indiastudy, stool examinations were only 
performed at baseline and not during 
follow up when the patient had 
developed TB (75). Clinically, patients 
with intestinal worms have been seen to 
have more severe radiological 
pulmonary disease with larger lung areas 
affected at the end of TB treatment (76). 
Regarding cytokine expression, 
peripheral blood mononuclear cells 
(PBMCs) from helminth-infected TB 
cases have been seen to produce less 
IFN-γ and more IL-10 and IL-5 in 
response to PPD (57, 76-78). However, 
other studies have surprisingly shown 
increased IFN-γ production in patients 
with intestinal worms (57). Some studies 
report higher frequencies of Foxp3+ 
TREGs cells in blood (78, 79) and other 
no difference (80). BCG-induced 
lymphocyte proliferation in vitro has 
been shown to be reduced in cells 
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isolated from worm-infected individuals (80). Furthermore, intestinal helminth infection has 
been associated with decreased reactivity in diagnostic tests, such as TST and the interferon 
gamma release assay (IGRA) (57, 71, 77), indicative of weaker mycobacteria-specific 
immune responses in these individuals. Consistently, presence of helminths has been 
suggested to affect performance and limit interpretability of the IGRA assays in children (81). 
In a study in South Africa, an inverse correlation between Ascaris IgE status and a positive 
TST test was found (82), however, a study in Venezuela showed positive correlation between 
TST positivity and helminth infection (83). In a study of DNA methylation patterns of CD4+ 
T cells in blood after helminthic disease, it was found that active Ascaris and S. mansoni 
infection alters methylation in a direction presumably negative for anti-TB immunity (84). 
The Ascaris-induced methylation was restored in people that had cleared the infection, 
whereas the S. mansoni-induced patterns remained and lasted six months after deworming 
(84). Importantly, deworming from intestinal helminth has been shown to significantly 
improve T cell proliferation and IFN-γ production and to restore IL-10, eosinophil and 
Foxp3+ cell levels in blood (78, 85). Dewormed individuals have also in some studies been 
seen to mount stronger PPD-specific immunity and TST reactivity after BCG vaccination 
compared to those still carrying worms (86-88), whereas other studies have shown no such 
effect (89). Clinical TB scores have been seen not to improve within the first two months 
after deworming (85).  
Similarly, some studies in animals indicate reduced TB protection in helminth-infected mice, 
whereas other show no effect (90). Pre-existing (five days) infection with N. brasiliensis have 
been seen to ameliorate aerosol M. tuberculosis infection in BALB/c mice, partly by inducing 
AAMs via the IL-4 pathway (91). Intraperitoneal N. brasiliensis infection of C57Bl/6 mice 
four days prior to intranasal M. bovis BCG caused lower mycobacteria-specific IFN-γ 
production in mediastinal LNs but no difference in BCG load (92). In BALB/c mice infected 
with T. muris followed by M. bovis BCG, CFUs and histopathology of the lung were similar 
between the two groups but specific cytokine responses to each organism were reduced in the 
co-infected mice (93). However, another study instead showed that N. braziliensis-infected 
BALB/c mice were more protected with lower bacterial load in lungs and increased IFN-γ 
production (94). Protection was mediated by macrophages and increased neutrophil 
recruitment to the lung (94). Further, other studies have shown no effect of pre-existing H. 
polygyrus or Toxocara canis infection on M. tuberculosis infection, despite dissemination of 
Foxp3+ regulatory T cells to the lungs and mediastinal LNs (61, 95). 
1.3.2 Intestinal helminths and Leishmania spp. 
Leishmaniasis remains one of the world’s most neglected diseases, affecting the poorest of 
the poor, mainly in low-income countries. Leishmaniasis is caused by flagellated protozoan 
parasites of the genus Leishmania. It is a vector-borne disease, causing risk of infection to 
increase with for example inadequate housing, open sewers, and outside sleeping, and is 
transmitted by blood-sucking female Phlebotomine sandflies. Similar to helminths, 
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leishmaniasis is severely understudied. There are three main forms of leishmaniasis with 
dramatically distinct clinical manifestations. Cutaneous leishmaniasis (CL) causes skin-
restricted lesions, whereas in mucocutaneous leishmaniasis (MCL), the lesions in addition or 
instead affect the mucus membranes. In visceral leishmaniasis (VL), the parasites infect 
visceral organs (e.g. spleen, liver and bone marrow) causing a highly lethal condition. The 
type of disease that develops depends largely on which of the around 20 Leishmania parasite 
species that has infected the patient (65, 67).  
CL causes the mildest symptoms but is the most common type of leishmaniasis with around 
600 000 to one million new cases each year (67). Lesions primarily develop at the site of the 
sandfly bite but parasites may disseminate and secondary lesions appear, often along the 
lymphatic vessels. Exposed skin which is more easily attainable for the sandfly, such as that 
of the face and hands, is mostly affected. Lesions often self-heal within a few months or up to 
two years, depending on infecting species. The highly visible lesions in concert with the 
association to poverty causes the disease to be stigmatizing, and concerns of scarification 
after healing are common. Healed infection causes life-long immunity. Parasites mainly 
reside in macrophages of the skin and skin-draining LNs (96). In some cases, certain species 
of Leishmania parasites, belonging to the brasiliensis complex, disseminate to mucous 
membranes such as mouth, nose and throat cavities, causing a more serious and difficult-to-
treat form of the disease, mucocutaneous leishmaniasis (MCL). Mucous membranes 
beocomes destructed causing disabling and stigmatization. Almost 90% of MCL cases occurs 
in Brazil, Peru, and Bolivia (67).  
The most severe form of leishmaniasis is the visceral type, also called Kala-Azar (Hindi for 
“black fever”), which affects around 50 000 to 90 000 individuals yearly and is close to 100% 
lethal without treatment (31). VL is associated with low-grade or intermittent fever, 
hepatosplenomegaly, weight loss and anaemia. The great majority (94%) of VL cases occur 
in only seven countries, namely Brazil, India, Ethiopia, Kenya, Somalia, South Sudan and 
Sudan. After the sandfly bite, parasites disseminate systemically and propagate in liver, 
spleen, bone marrow and LN. In general, therapy is expensive and toxic with significant side 
effects, but has a high rate of success. Patients who suffered from VL caused by L. donovani 
may develop a sequel of skin manifestations termed post kala-azar dermal leishmaniasis 
(PKDL). PKDL patients lack the clinical signs of VL, and inversely, the skin of VL patients 
look histologically normal. Parasites are however found in the skin of VL patients, where 
they are believed to be evade and survive treatment (97). Similar to the situation with TB, 
only around five to ten percent of infected individuals develops VL. What makes a patient 
progress to active disease is not clear, but is known to be affected by the immune status of the 
patient (67, 98-100) 
Very few studies have been published on the association between intestinal helminths and 
Leishmania infection in humans. In a study in in Brazil, intestinal helminths were associated 
with poor response to Leishmania therapy in cutaneous forms of leishmaniasis caused by L. 
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braziliensis (101). This was accompanied by an immune response shifted toward TH2 and 
higher eosinophil counts (101). The reduced therapy response was repeated in another study, 
when also higher prevalence of mucosal lesions was noted in worm-infected patients (102). 
However, a third study in the same region showed no difference in success of L. braziliensis 
treatment between worm-infected patients receiving anti-helminthic treatment immediately or 
60 days after initiation of the Leishmania therapy (103). A possible explanation for the 
discrepancy may be that the immunological effects of the helminths remain long after 
removal of the worms, masking potential effects of deworming. In a study aiming at evaluate 
the association between intestinal helminths and VL in humans, no obvious association 
between the infections nor any difference in L. donovani load between worm-infected and 
worm-free individuals was noted ((104), own unpublished data). However, a larger sample 
size would be required to credibly exclude such an association (104). 
In animals, the magnitude of footpad swelling after L. major infection have been shown not 
to be altered by concurrent or five days pre-existing N. brasiliensis infection (nor by IL-4 
treatment) of C57Bl/6 mice (105). However, blocking IL-4 in BALB/c mice increased 
control of L. major infection (105). In C57Bl/6 mice infected with Strongyloides ratti in the 
footpad, followed by L. major infection in the same footpad six days later, the pre-existing S. 
ratti did not influence control of L. major, but even enhanced proinflammatory cytokine 
production in the draining LNs (106). 
1.4 THE SKIN 
Our skin is the major barrier between us and the outside world. The average human has a 
surface skin area of around 1.8 m2 and the skin accounts for approximately 16% of the body 
weight. The skin provides one of our first lines of defence against the external environment, 
protecting us from mechanical, chemical, and microbial damage (107). 
The skin is divided into two main compartments: the outer epidermis and the inner dermis. 
The epidermis mainly consists of keratinocytes, but also a few immune cells. The outermost 
layer of the epidermis, the cornified layer (stratum corneum), consists of dead keratinocytes 
called corneocytes that gives the skin its rigid structure. Corneocytes are terminally 
differentiated cells that have lost their nucleus and cytoplasmic organelles. Underneath lies 
the translucent layer (stratum lucidum, only found in palms and soles) followed by the 
granular layer (stratum granulosum), in both which the cells also lacks nuclei. The next layer 
is the first one consisting of living cells, the spinous layer (stratum spinosum), where the 
keratinocytes are connected with cell-to-cell junction proteins called desmosomes. The final 
layer (stratum basale), is one cell layer thick and contains keratinocyte stem cells. The basal 
layer contains melanocytes responsible for pigmentation of skin by producing melanin. The 
human epidermis consists of between five to ten layers of live cells, whereas mouse skin only 
has two to three layers. Turnover time of keratinocytes from basal layer is 40-65 days in 
human skin but only eight to ten days in mice. However, the most prominent difference 
between human and mouse skin is probably the hair follicle density, resulting in fury skin in 
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Figure 8: Architecture and immune cells of the skin.
The skin consists of an outer epidermis (comprising
several layers) and an inner dermis. In epidermis, LCs and
CD8+ T cells are most common cells, whereas in the
dermis the immune cell community is more diverse.   
mice. The epidermis is not vascularised or enervated, as oppose to the underlying layer – the 
dermis. In between the epidermis and dermis lies a basement membrane to which both are 
attached. The dermis is mainly made up of extracellular matrix, fibroblasts, and structural 
cells, but also some immune cells. The dermis in turn is supported by underlying 
subcutaneous tissue, mainly consisting of fat, that separates it from the muscular layer (107-
111).  
1.4.1 The cutaneous immune system 
Immune cells are relatively sparse in skin. Yet, due to its large surface, the skin contains a 
sizeable total number of immune cells. It has been estimated that human skin comprises 
approximately twice as many T cells as the circulation (112). The few immune cells found in 
the epidermis are located in the spinous layer, and mainly consists of αβ T cells (mostly 
CD8+), and Langerhans cells (LC). LCs comprise a unique type of DC only found in the 
skin, where they with long protrusions constantly survey and sample their surroundings. 
Further, a type of γδ T cells unique to the skin called dendritic epidermal T cells (DETCs) is 
common in mice but seem mostly absent in humans. Dermal immune cells include DCs, 
macrophages, αβ T cells (equally many CD4+ and CD8+ cells), γδ T cells, plasma cells, and 
ILCs (108, 112, 113) 
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1.4.2 The gut-skin axis 
A large part of this thesis addresses the skin and the gut, however, not as separate entities, but 
rather the link between the tissues and more specifically, what implications an intestinal 
infection may have on skin. The gut and skin are seemingly different and far apart, yet, the 
two tissues have a lot in common. Both are barrier tissues and provide a first line defence 
against pathogens, requiring resilient structures and robust immune protection. Yet, both also 
encounter an immense number of harmless substances such as food, commensal microbes 
and environmental material (114). 
That there are associations between pathological conditions in the gut and the skin have for 
long been appreciated in the clinic. For example, constipation and increased intestinal 
permeability are associated with acne, Helicobacter pylori infection (a bacteria often linked 
to stomach ulcers) as well as small intestinal bacterial overgrowth (SIBO) are associated with 
rosacea, inflammatory bowel disease (IBD) with psoriasis, and coeliac disease with dermatitis 
and psoriasis (114, 115). Many studies indicate associations between diet and inflammatory 
status in the skin. Possibly the greatest interest has been shown in the probiotic field, which 
hopes to provide us with more resilient skin and shinier hair. For example, mice and humans 
given Lactobacilli as oral probiotics has been seen to acquire increased dermal thickness and 
barrier functions, which was associated with increased levels of anti-inflammatory cytokines 
systemically (115, 116). Oral Lactobacilli treatment has also been shown slightly protective 
against atopic dermatitis (114, 115, 117, 118). Further, oral antibiotics early in life of mice 
has been seen to increase susceptibility to imiquimod-induced psoriasis (119). A few 
mechanisms of crosstalk have been proposed, involving metabolic, neuroendocrine, and 
immunological pathways or the partly shared microbiota (114). Recently, mice infected with 
H. polygyrus were seen to be less susceptible to a model of skin contact hypersensitivity by 
an unknown mechanism independent of TREGs (120). In general, not much research has been 
conducted if the crosstalk between intestine and skin and the so called “gut-skin” axis is a 
quite new concept (114). 
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2 AIMS 
Intestinal helminth infection has systemic implications on the host’s immune system and has 
been suggested to affect vaccine responses and immunity to other infections. In general, little 
is known about the consequences intestinal worms have on host immunity. 
The overall objective of my PhD studies was to better understand the impact of intestinal 
helminths on immune responses distal to the gut, primarily effects on skin immunity and on 
control of co-infection.  
More specifically, the aims were:  
 To elucidate the effects of H. polygyrus on co-infection and skin immunization with 
TH1-controlled pathogens (Paper I). 
 
 To evaluate the impact of H. polygyrus infection on secondary infection with  
L. donovani (Paper II). 
 
 To find the mechanism behind the reduced skin response to M. bovis BCG in worm-
infected mice, seen in Paper I (Paper III). 
 
 To investigate the effects of H. polygyrus on skin T cells (Paper IV). 
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3 ETHICAL CONSIDERATIONS 
Intestinal helminth infections are severely understudied. Both helminthiasis and leishmaniasis 
are on the list of diseases which WHO classifies as “neglected tropical diseases”, meaning 
that the amount of resources spent on research and control of the diseases are substantially 
less than the morbidity and mortality they give rise to. TB is not classified as neglected, but 
despite persistent efforts to stop the TB pandemic, the disease still kills and disable vast 
numbers of people each year. All approaches to increasing the efficacy of the BCG vaccine 
should therefore be considered (31).  
Approximately 350 000 animals were used for medical research in Sweden in 2016. Thirteen 
percent of these were used to study the immune system in one way or another (121). 
Alternative methods to animal research are constantly being developed and techniques such 
as organoids, safety evaluations for using human volunteers, computational modelling, and 
advanced cell culture systems win increasing amounts of grounds in research. Despite intense 
development of new techniques, there are still many phenomena impossible to study without 
using animals. The questions addressed in this thesis involve mechanistic investigations of 
systemic effects by a localized infection. There are so far no substitutes to whole animal 
models to understand the interactions between distal tissues, since the complete organism and 
the possibility to collect multiple tissues at the end of the experiment are required. Yet, there 
is a huge need for this type of knowledge. To better understand the effects of intestinal 
helminths on vaccine responses and control of co-infection would enable better targeted 
interventions that could improve quality of life for many. 
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4 BRIEF SUMMARY OF RESULTS 
With the work included in this thesis, we have seen that H. polygyrus infection have 
widespread implication on its host’s immune system, affecting lymphocyte distribution, skin 
immunity, and control of co-infection.  
In Paper I we found that worm-infected mice mount weaker immunity to systemic infection 
by M. bovis BCG, reduced DTH responses to BCG and Leishmania and less DC migration 
from skin to draining LNs. In Paper II, we found that worm-infected mice are less protected 
against systemic infection with L. donovani. In Paper III we searched for the mechanism of 
reduced skin immunity of worm-infected mice found in Paper I and discovered that skin-
draining LNs were drained of cells, leaving them atrophic. We found so signs of 
dissemination of type 2 or regulatory cells to skin-draining LNs that would explain the 
reduced priming efficiency in worm-infected mice. Mesenteric LNs were, as expected, 
extensively expanded in worm-infected animals. In Paper IV, H. polygyrus-specific type 2 
CD4+ T cells were found to accumulate in the skin and remain after deworming. Skin 
homing chemokine receptors were upregulated in the mesenteric LNs and blood.  
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5 DISCUSSION 
The four papers included in this thesis all address the effects of infection by the strictly 
intestinal nematode H. polygyrus on the host immune system. H. polygyrus, and intestinal 
worms in general, are extremely multifaceted in ways of affecting host immunity, and with 
each study we found new means of modulation. Below follows an integrative discussion that 
aims to place our new findings into a wider perspective. First, choice of mice, models and 
methods, will be discussed. 
1.1. Mice 
All data generated for this thesis are based on experiments in mice with C57Bl/6 background, 
a strain known to be skewed towards TH1 in their immunological response (45). Intestinal 
helminth infections in humans and animals often becomes chronic, and the TH1 bias in 
C57Bl/6 mice similarity causes H. polygyrus to linger and become chronic. BALB/c mice on 
the other hand, which have stronger TH2 response, usually clear H. polygyrus infection during 
the effector phase of the TH2 response and does not establish chronic infection. In humans, 
the distribution of helminths is uneven in a population, as a minority of individuals often 
carry a large proportion of the worm burden and are traditionally referred to as “wormy” 
people (122, 123). The reason has been suggested to be a variety of the TH1/TH2 gene ratio in 
the population, where the wormy people are, similarly to C57Bl/6 mice, TH1 prone, and the 
non-wormy people TH2 prone, similar to, BALB/c mice. Some of our findings we also tested 
in BALB/c mice. For example, in coherence with the requirement for chronicity for TH2 cell 
accumulation in skin, CD4+ T cells did not accumulate in skin of BALB/c mice (own 
unpublished observations). However, skin-draining LNs were atrophic also in H. polygyrus-
infected BALB/c mice (own unpublished observations). 
Intestinal helminth infections are most frequent in school aged children, even if some species, 
mostly hookworms, are also common in adults (32). In an attempt to mimic this, we infected 
mice at a young age (four to five weeks of age) in most experiments, followed by secondary 
infection when the worm infection was considered chronic. A mouse at four weeks of age has 
passed the weaning stage and are just about to become sexually mature, hence can be 
compared to a school aged human child (124).  
In Paper I, II and III, both female and male mice were used. Male mice were in many 
instances preferred, since they tend to keep the infection for longer ((45) and unpublished 
observations). In Paper II however, when the skin itself was analysed, the fact that male mice 
tend to fight more left no option but to choose female mice, as the risk of having to exclude 
animals due to skin scratches was too large with male mice. This have caused some 
difficulties in comparisons between the studies, as the female mice have ended up with a 
lower worm load or in some cases cleared the infection before the time of analysis. However, 
mice were always age and sex matched within a single experiment.  
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We have during the time of these studies moved our laboratory facilities, changed animal 
house and switched from inhouse breeding of C57Bl/6 mice into purchasing from vendors. 
Despite being the same strain of mice, this have likely caused differences in genetic makeup 
and the microbiota of the mice, which may also have caused differences between studies.  
1.2. Models 
We have used H. polygyrus as a model for intestinal worm infection, Mycobacterium bovis 
BCG, L. donovani and L. major as models for mycobacterial and leishmanial disease 
respectively, and DSS-induced colitis as model for non-infectious intestinal inflammation.  
H. polygyrus in a strictly intestinal worm, without any systemic migratory route. In humans, 
strictly intestinal helminth species are less common then migrating ones (32). Yet, the 
migrating species spends the majority of time in the intestine and only a brief period in other 
organs (years versus days). Since organs distal from the intestine have been studied, it is 
likely that a migrating or systemic helminth model would have in some experiments yielded 
more pronounced results (e.g. co-infection with systemic TH1 organisms and skin 
lymphocytes), whereas other results might not have at all been discovered (e.g. atrophy of 
skin-draining LNs). Helminth models where infection is performed subcutaneously such as 
N. brasiliensis or the Strongyloides species, would have caused difficulties in sorting out 
which reactions were effects of migratory larvae and which were due to actual dissemination 
of responses. T. muris is strictly intestinal but only causes acute infection in most mouse 
strains, and many of our key findings were not significant until the chronic stage of H. 
polygyrus infection, including DTH responses to mycobacteria, atrophy if skin-draining LNs, 
and TH2 cell accumulation in skin. Other investigators have studied the effects of systemic 
helminths on mycobacteria and Leishmania infection, with varying outcome depending on 
model of choice. Some studies on mycobacteria indicate an detrimental effect by the worms 
(125-127) whereas other show no difference (64, 128, 129). On Leishmania, some studies 
show that helminths have negative effects for protection against Leishmania (127, 130-133). 
Surprisingly however, other studies show beneficial effects by the worms. Protection to L. 
donovani due to cross-reactivity has been seen in hamsters infected with the filarial nematode 
Brugia malayi (134, 135), underscoring the complexity of this type of studies. 
In most experiments, we infected mice with a quite high dose (200-300 larvae) by a bolus 
injection. Both dose and means of injection is standard in the field which facilitates 
comparison of results to studies of other researchers (45). In nature, one could assume that 
helminth infection rarely occurs as a single high dose, but rather by low but continuous 
exposure. Such “trickle infection” of H. polygyrus has been employed by others with similar 
results as a single bolus infection, where TH2 prone mouse strains got rid of the infection 
whereas TH1 prone strains accumulated worm burden (136). No further examinations on the 
dissemination of HES have been performed during our studies. One could argue that this 
would have been of importance due to the nature of our questions, and future projects will if 
feasible entail such experiments. 
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We used the attenuated vaccine strain M. bovis BCG to study mycobacterial infection and 
vaccine responses in order not having to consider the confounding safety precautions 
associated with more virulent mycobacteria. In the experiments attempting to understand 
actual BCG vaccine immune response, this was also scientifically more appropriate. In Paper 
I, BCG was injected systemically, which is not the normal route of vaccination nor infection. 
Yet, these experiments gave general insight into the effects of intestinal helminths on 
infection with systemic TH1 organisms. Similar results were obtained from the L. donovani 
co-infection model, which provided more credibility to both studies. Two types of 
Leishmania parasites have been employed during our studies, one skin tropic (L. major) and 
one visceralizing (L. donovani) to investigate the impact of H. polygyrus on skin and 
systemic infection, respectively. Other Leishmania species of similar tropism might have 
given other results, yet, the chosen parasites are two of the dominating Leishmania species 
world-wide (137). 
The policies and practices of BCG vaccination differs between counties. In most developed 
countries, such as Sweden, BCG is no longer a part of the general vaccination program but is 
instead only given to risk groups. In many other countries however, BCG is still the first 
vaccine a child receives after birth, and in some, booster vaccinations are given around school 
age (74). This means that few individuals in endemic regions will actually be exposed to 
helminths before receiving the BCG vaccine, and one can argue that the opposite 
experiments, to immunize with BCG prior to the helminth infection would provide a more 
realistic scenario. Such experiments have been performed by us and others, with some results 
indicating decreased helminth control and others showed no difference ((92, 93) own 
unpublished data). Yet, the experimental setup used for our studies have provided valuable 
information that can be extrapolated to implications on efficacy of other vaccinations.  
Incidence of VL is highest between five to 20 years of age (138), and CL is also more 
common in younger individuals (139). The overlapping age span of helminths and 
Leishmania infections increases the likelihood of the same individual being infected with 
intestinal helminths while being exposed to Leishmania and emphasizes the relevance of 
worm and Leishmania co-infection studies. The inverted setup have also in the case of 
Leishmania been studies by others, where superimposed Leishmania infection have in some 
instances caused reduced control of the worms and in other studies not altered the outcome 
(106, 127, 131, 140, 141).  
1.3. Hypothesis evolution 
Before the work in this thesis was initiated, it was well established that helminths induce type 
2 and regulatory responses whereas mycobacteria and Leishmania requires TH1 responses for 
protection, as well as that TH2 and regulatory responses dampens TH1 responses (57, 142). 
That this would be the mechanisms of which H. polygyrus dampened responses to 
mycobacteria and Leishmania spp. was naturally our primary hypothesis.  
 42 
Both Paper I and Paper II proposed that the reduced protection against systemic BCG and L. 
donovani infection, respectively, was due to decreased inos expression and granuloma 
formation in livers. In Paper I, we proposed that increased TGF-βR signalling contributed to 
weaker control of infection, diminished DTH responses to mycobacteria and Leishmania, 
downmodulation of DC migration from skin to draining LN, and other immune dampening 
effects observed in worm-infected mice. This was based on that H. polygyrus products did 
(similar to TGF-β) decrease BCG-induced DC migration and downregulated BCG-induced 
IFN-γ production in vitro in a TGF-βR-dependent manner. In addition, worm-infected mice 
had increased frequency of LAP-expressing cells (a substitute measure for TGF-β) in spleen. 
In Paper III, aiming to further elucidate the mechanisms of H. polygyrus-mediated dampening 
of skin responses to BCG, we found that the atrophy of skin draining LNs observed in worm-
infected mice better explained worm-mediated immunosuppression, as no dissemination of 
regulatory nor type 2 responses was observed in the skin-draining LNs. During the course of 
our study (in 2017), King et al published a paper supporting our theory (143). The authors 
saw that H. polygyrus-infected mice had muted responses to pneumococci-vaccine and 
influenza infection, delivered in the footpad and intranasally (respectively), and had atrophic 
draining LN at both sites (143). In Paper IV, we found an accumulation of H. polygyrus-
specific TH2 cells in the skin of helminth-infected mice that was suggested to also contribute 
to reduced IFN-γ production in response to mycobacterial WCL skin injection. Reports 
published by other investigators during the course of this work also suggest extraintestinal 
TH2 memory cell deposition after H. polygyrus infection, supporting our findings (45, 53, 
60). In light of these new discoveries, it is possible that the TGF-β mediated mechanism seen 
in Paper I is of lesser importance for worm-mediated immunosuppression of skin responses 
than first suggested. As an alternative, it is likely that reduced skin immunity is due to a 
combination of local increase in TH2 cell abundance and reduced priming in the atrophic skin 
draining LNs, found in Paper IV and III, respectively.  
1.4. Mass drug administration or helminth therapy? 
The WHO encourages deworming by mass drug administration (MDA) to school aged 
children once or twice yearly (for areas of >20% and >50% prevalence, respectively) without 
diagnosing infection, in order to reduce the helminth burden in the population (31). The 
benefits of these de-worming programs are however debated, as the high incidence of re-
infection may render them useless and that they may contribute to development of 
anthelminthic resistance, a widespread problem in veterinary medicine (31, 144-147). Yet, 
due to the morbidity caused by intestinal worms and especially for those with high load 
infection, the beneficial consequences of MDA are by many considered to outweigh the 
negative effects (148, 149).  
There are two sides to every coin, fascinatingly also to the impact of intestinal worms on our 
immune system. With the economic development and increased availability of hygiene 
facilities in Western countries, worm infections have largely disappeared, and suddenly, a 
notable fraction of humans are worm-free. Not long ago it was norm rather than exception for 
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all humans to be infected with at least one intestinal helminth species. The mammalian 
immune system has been shaped in presence of intestinal worms which has resulted in an 
intricate relationship between host and parasite. Thus, it would not be surprising if the abrupt 
elimination of parasitic worms has had impact on the immune system of the modern human. 
Eradicating intestinal parasites has been suggested to play a part in the increase of 
inflammatory, asthmatic, allergic and autoimmune diseases we see in the Western world 
today (63, 150, 151). This notion was first postulated in the 19th century  when it was noticed 
that people living in urban areas had higher prevalence of hay-fever compared to rural 
populations, and was later coined “The Hygiene Hypothesis” by David P. Stratchan in 1989 
(152). Lately, this have raised the idea of reintroducing helminths into our bodies hoping that 
the worm-induced regulatory responses would dampen immuno-pathologies. Even though 
impressive results have been seen in experimental animal models, they have not been 
successfully replicated in human trials (153, 154). There are also obvious concerns with using 
live helminths for therapy, including safety issues for the host (especially for 
immunosuppressed individuals), risk of spread to other individuals, and that many patients 
might not feel comfortable with such a treatment. Instead, the potent immunoregulatory 
effects seen by isolated ES products have raised the idea to exploit these mechanisms for 
therapeutic use (51). Administration of ES products in animal models have been shown to 
inhibit intestinal inflammation in models of colitis, EA, T1D and collagen-induced arthritis 
(51, 153, 155).  
1.5. Translatability and clinical importance 
While animal models provide an excellent tool to demonstrate a proof of principle, the 
transability to humans by this type research should be interpreted with caution. H. polygyrus 
does not infect humans and none of the most important human intestinal helminths infects 
mice. Mice do not develop similar disease to L. donovani infections as humans and 
intravenous injection of BCG is an artificial rout of infection. The lesions from L. major and 
BCG skin injections however have clinical similarities to those of humans. Despite being a 
commonly used model of IBD and irritable bowel syndrome (IBS), DSS-induced colitis does 
not capture all aspects of either disease.  
However, the immune responses evoked by helminth, Leishmania ssp., and mycobacterial 
infections share large similarities between mammals and the value of these models to 
understand immunity to infection have been enormous. Mice and human share many features 
of lymphocyte migration, TH cell orchestration, counter-inhibition between TH cell subsets, 
and protective responses during infection. Hence, when the primarily goal as in our case is 
not to study the pathogenesis of a particular organism or disease, but rather to get an 
understanding of the immunological responses to that agent, mice provide a tool of 
unmatched value for new insights. Similarly, the aim with the DSS was to induce intestinal 
inflammation rather than to study IBS or IBD disease pathogenesis.  
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Paper I, III and IV support previously published studies, but also provide new suggestions 
that can explain why BCG vaccinations are less efficient in certain parts of the world. 
Considering the weak protection BCG provides against pulmonary TB in adults, the massive 
amounts of people infected, and the continual high numbers of death due to TB, every 
contribution to more robust mycobacterial immunity should be considered. Whether worm-
infected humans actually have smaller skin-draining lymph nodes and more TH2 cells in skin 
remains to be elucidated. If so, it is possible that also other skin infections would be 
aggravated in worm-infected individuals. In addition, if what our data and others suggest is 
correct, worm-infected people would have weaker DTH responses to BCG. This does not 
only have consequences on vaccine efficacy, but possibly even more importantly, worm-
infected individuals with suspected TB may be less likely to be properly diagnosed by TST. 
Failure to find TST positive individuals may have implications both for the individual by 
potentially delaying treatment, but also for clinical studies that may underestimate the 
prevalence of TB in a population.  
Co-infection studies between intestinal worms and leishmaniasis in humans showed no 
association between the diseases (104). That our studies in mice (Paper II) and in humans 
showed different results can have many reasons. For example, mice are not diseased by the 
infection, lacking fever and rampant parasite propagation. It is possible that VLs disease in 
human cause an unpleasant environment for the worms. In addition, in mice, we solely study 
the immunological features of co-infection, excluding epidemiological and vector-associated 
parameters. Hence, the result from Paper II may not be directly translatable to human VL. 
Yet, considering the findings on systemic M. bovis BCG in Paper I, Paper II provides 
additional support for that intestinal worms may affect systemic immunity to TH1 controlled 
organisms 
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6 CONCLUDING REMARKS 
Intestinal helminth infection has profound effect on the host’s immune system. Our results 
support the notion that removal of worms may improve vaccine efficacy and control of co-
infection. The rate of reinfection after treatment of worms is extremely high (144). Most 
likely, improved sanitary conditions would instead or in combination with treatment better 
reduce the burden on intestinal helminthiasis in a society. However, there are also positive 
effects of intestinal helminths, and ideally, we could learn how to utilize these without the 
negative consequences of infection. Hence, to better understand the effects intestinal worms 
have on our immune system will not only help us to get rid of an ancient disease, but also 
provide cues for innovative future solutions. 
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